.Nature Medicine, Published online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) therapy of people with HER2+ innovative bosom cancer cells as well as active or even secure human brain metastases showed consistent intracranial activity and systemic efficiency of T-DXd.